Streetwise Reports' Article Archives — Current Month (98)
Part 2: Who Should Be Your Broker: Exploring which broker may be right for you.
The two firms are bringing together lighting, cameras and analytic technology.
A recent acquisition is helping this company to expand its brand.
Best Brokers for Research (11/20/2019)
Part 3 of Streetwise Reports' Online Brokerage series delves into the research brokerage firms offer.
The Calgary-based oil & gas company states the transaction will add shareholder value and strengthen the balance sheet.
With the funds, the Canadian company will fast track a drill program at its Idaho gold property.
All four are Carlin-type gold targets.
Two Projects in Ecuador Mark 'Turning Point' (11/20/2019)
One project is in the exploration stage, while the other officially opens.
Explorer Drills 37.95 g/t Gold at BC Project (11/20/2019)
The company now intends to update the resource estimate.
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis.
In conversation with Maurice Jackson of Proven and Probable, the CEO of this firm talks about prospects in Nevada and Canada's Yellowknife district, and discusses the company's financial strategy.
With preparatory work there now finished, that mine area is ready for drilling.
Part 1: What It All Means for Investors: Online brokers as investments.
Bob Moriarty of 321gold, in conversation with Maurice Jackson of Proven and Probable, expounds on his views of geopolitics, and discusses metal prices as well as a number of mining companies that he finds attractive right now.
Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20.
Torchlight Firing on All Fronts in Texas (11/18/2019)
The company continues to prove up its holdings as it searches for a partner.
Over the past 20 years, this company's shares have outperformed gold by more than five to one.
Premier Health is methodically building an innovative telemedicine platform in Canada, is purchasing a venerable telemedicine firm, and sees 2020 as the year of execution.
There are 46 claims on the Quebec property being purchased.
Services include development of augmented reality holograms and three-dimensional AR assets.
Firm to Acquire CBD Products Designer (11/18/2019)
The deal encompasses all of the company's brands, formulations and processes.
The Canadian company states it is well positioned financially for future activities.
Gross margins increased to 29% from 13% QoQ.
If History Repeats, Gold Is Headed to $8,000 (11/18/2019)
Sector expert Jason Hamlin explores the potential of the current gold bull market by charting the courses of past bull markets.
Sector expert Michael Ballanger interprets the latest market moves and manipulations.
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia.
Bob Moriarty of 321gold discusses the Daily Sentiment Index and what it could mean for the markets.
Starwood Research takes a look at the investment proposition offered by this tech company, asserting it is the only "pure play" stock targeting four multibillion-dollar market opportunities.
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth.
Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital.
Uranium Firm Divests Kyrgyz Assets to Focus on US (11/14/2019)
Political uncertainty around uranium mining there and the company's desire to focus solely on its U.S. assets prompted the sale.
Two wells in Thailand are producing oil, and the drill program continues.
Explorer Discovers High-Grade Oxide Zone in Nevada (11/14/2019)
The company will further explore the target where it made this discovery.
This advancement has been long sought by the industry.
Looking for Gold in Elephant Country (11/14/2019)
As Newrange Gold shifts its focus to Nevada, it is monetizing its Colombian properties to fund exploration.
These efforts are scheduled to be carried out in winter 2020.
The company was active at its two main assets.
Palamina Wants to Ride the Golden Pony in Peru (11/14/2019)
Bob Moriarty of 321gold profiles one of the very few pure gold plays in Peru.
Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million.
A shift in the industry leads to big new contracts and parabolic stock performance for this small cap.
The company is starting off with a resource of close to a million ounces of gold before drilling.
The terms and the reason are presented in a Mackie Research Capital Corp. report.
The details of this transition project in Nevada are discussed in a CIBC report.
This small-cap firm's threat detection products have evolved from a single technology to a multi-sensor threat detection platform.
The company intends to follow up in 2020 with a Phase 2b clinical trial.
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report.
The online presentation coincides with The Liver Meeting 2019, at which data also are shared.
Mickey Fulp, the Mercenary Geologist, sits down with Maurice Jackson of Proven and Probable to discuss silver and its position among the metals, as well as some of his favorite copper, gold and uranium companies.
Shares of SmartVest maker Electromed traded 25% higher today after the firm reported Q1/20 earnings. The firm's shares set a 52-week high price after reporting a 14.1% increase in year-over-year quarterly revenue and a six-fold increase in net income per share.
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis.
Technical analyst Clive Maund explains why he believes this augmented reality stock is ready for its next leg up.
A new advancement in bladder-related endoscopic surgery is endorsed and de-risked.
Results will assist in delineating future potential drill targets there.
Significant events involving the firm took place during those three months.
Gold and Silver: Capitulation Time (11/12/2019)
With gold and silver prices having tumbled, sector expert Michael Ballanger outlines how he will weather the storm.
Bob Moriarty of 321gold profiles a company with historical gold mines in California.
Shares of melanoma and other skin cancers diagnostic firm Castle Biosciences Inc. traded more than 15% higher today after the firm announced Q3/19 financial and operational results.
Shares of TV shopping and online commerce kingpin Qurate Retail traded 10% higher today after the company reported Q3/19 earnings.
White Gold Delivers, Investors Don't (11/10/2019)
Bob Moriarty of 321gold discusses the stock price of this explorer with a major gold resource in the Yukon.
The Critical Investor looks into the uranium explorer's work in Argentina and the political situation in the country with the recent election of a new president.
Among other transactions, the company acquired four producing or near-producing royalties.
Drill results suggest the company's mineralized trend is part of a larger system.
For one, the company discovered the alkaline gold system there is much larger than initially thought.
The Critical Investor does a deep dive into this explorer's drill program at its Yukon silver project.
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial.
This is a significant milestone for the company, aiming to complete alpha testing by year-end.
Further drilling is planned to increase the project's now existing resource.
The company is moving ahead with uranium exploration in the high-grade Athabasca Basin amid a changing supply and demand paradigm.
Lion One Hits Bigly (11/07/2019)
Bob Moriarty of 321gold discusses the implications of the drill results the company released at its gold project in Fiji.
Glucose monitoring systems developer Dexcom's shares traded 30% higher today after releasing Q3/19 earnings and raising full-year 2019 guidance.
ProMIS' preclinical treatment could possibly outshine Biogen's candidate.
The company also connected two mineralized zones there.
The new user is an eyewear company, part of a sizable and growing market.
Gold Explorer Upgrades Listing to OTC Top Tier (11/06/2019)
The change is now in effect.
The short-term outlook for the Canadian company is provided in a CIBC report.
The producer's Q3/19 financial and operating results are reviewed in an iA Securities report.
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month.
US Uranium-Vanadium Miner Provides Quarterly Report (11/05/2019)
The company is processing ore from clean-up material at a past-producing uranium mine.
It will use the proceeds to explore and advance its project in Nevada.
Thirty-one dealer partners were added in the last month.
With gold prices above $1,500/ounce, Thibaut Lepouttre of Caesars Report runs the numbers to see whether this mine might be worth taking another look at.
'Exciting' U.S. Drone Stock Begins Trading (11/05/2019)
Technical analyst Clive Maund discusses a drone stock that begins trading today.
Fulgent Genetics shares traded more than 40% higher today after the company reported record revenue in Q3/19. The firm noted that it completed a record 20,697 billable tests in Q3/19, up 272% over the same period last year.
The Critical Investor delves into a lithium company's financing and its implications.
Defense Metals Drills High Grade REOs (11/05/2019)
Bob Moriarty of 321gold dives into rare earth elements and one company exploring a high-potential property in British Columbia.
I'm Mad as Hell: Long Live Howard Beale (11/04/2019)
Sector expert dissects recent Fed and other government actions and discusses his recent precious metals trades.
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20.
As security concerns grow in the West over Chinese-made drones, this North American manufacturer could take off.
With these efforts, the Vancouver-based company moves closer to developing a mineral resource estimate.
Both of these events are significant achievements for the company.
This new partner seeks to employ the company's telemedicine/mobile health system.
One, which was large, high grade and within meters of surface, is of major import.
It is completing this work while continuing its search for a company to develop one of its projects.
The company remains on a rapid growth trajectory.
This product will offer consumers a lower price point for market entry.
The Canadian company expects to release the results early next year.
In conversations with Maurice Jackson of Proven and Probable, Jayant Bhandari offers his thoughts on geopolitical unrest in the Middle East, Latin America, and elsewhere, and how these issues affect the precious metals markets and the accumulation of wealth.
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership.
|"This looks like an excellent time to take positions in NRG."|
|"PGE is on the radar of majors but under the radar of investors."|
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|
|"North Boundary at ABN's Forrest Kerr remains open at depth."|
|"SCAN signed an agreement with Port Tampa Bay to beta test HEXWAVE."|